Zydus Lifesciences Receives USFDA Approval for Generic Anti Parasitic and Leprosy Drugs
Zydus Lifesciences announced on Saturday that it has received approval from the US health regulator to market generic versions of two important medications used for treating parasites and leprosy.
The Ahmedabad-based pharmaceutical company confirmed it has received final approval from the US Food and Drug Administration (USFDA) for Ivermectin Tablets (3 mg) and Dapsone Tablets (25 mg and 100 mg).
Understanding the New Approved Medications
Ivermectin Tablets (3 mg) Ivermectin is a prescription anti-parasitic medication. It is primarily used to treat infections caused by parasitic worms in humans. Specifically, it is prescribed for:
- Intestinal strongyloidiasis: An infection in the gut.
- Onchocerciasis: Also known as river blindness.
Dapsone Tablets (25 mg and 100 mg) Dapsone is used as both an anti infective and an antibacterial agent. These tablets are primarily indicated for:
- Leprosy: Treating and managing the disease.
- Dermatitis herpetiformis: A chronic, itchy skin condition.
The medication helps control skin lesions and manages the symptoms associated with these conditions effectively. With these new approvals, Zydus continues to expand its portfolio of affordable generic medicines for the US market.
Also Read : February 2026 Explained AI Concerns, Trade Tariffs, and Cricket Highlights
